Nanocis (Rhenium Sulfide)

The exact pharmacological action of Rhenium Sulfide is not fully disclosed. Early studies suggest it may bind to metal‑dependent proteins and influence cellular redox pathways, which could affect cell growth and survival. Ongoing research aims to clarify its mechanism.

Dosing of Nanocis is determined by the prescribing investigator or clinician based on the specific study protocol or clinical context. No standard dose is publicly established, and the regimen should be individualized by a qualified healthcare professional.

Safety data for Nanocis in pregnancy or lactation are not available. Until further information is obtained, it is generally advised to avoid use in pregnant or nursing individuals unless the potential benefit justifies the potential risk and is approved by a specialist.

To request Nanocis, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and required import documentation.

Nanocis is distinguished by its Rhenium Sulfide core, a metal‑based molecule not commonly found in other investigational drugs. While comparative efficacy data are limited, its unique chemical structure may offer different pharmacologic properties compared with small‑molecule or biologic candidates in similar therapeutic areas.

Nanocis should be stored at ambient temperature below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and follow any additional handling instructions provided with the shipment.

Nanocis can be given orally or by subcutaneous injection, depending on the study protocol. Administration routes, preparation, and dosing schedules are defined by the treating investigator and must follow the specific clinical trial or treatment guidelines.

Serious risks are not fully defined due to limited clinical exposure. Potential concerns include hypersensitivity reactions and unknown systemic effects. Patients should be monitored closely for any adverse signs, and any serious event should be reported to the overseeing clinical team.

Nanocis should not be used outside of a controlled clinical setting or by individuals with known hypersensitivity to metal‑based compounds. It is also contraindicated in patients where the investigational risk outweighs potential benefit, as determined by the responsible clinician.